Uncategorized Archives - Page 2 of 3

BMS, Takeda, Celgene, Boehringer-Ingelheim & Biogen will Speak at 2nd Annual MarketsandMarkets Real-World Data & Life Science Analytics Congress

September 5, 2019September 5, 2019 MarketsandMarkets Conferences

Boston, USA, 5th September – 2nd Annual MarketsandMarkets Real-World Data & Life Science Analytics Congress will be hosting industry giants like Bristol Myers Squibb, Takeda, Genentech, Boehringer-Ingelheim, Celgene and Biogen will take place at the DoubleTree by Hilton Boston-Downtown on 25th & 26th October 2019. Presenting 20+ RWD case studies, the congress aims to discuss accelerating the adoption of Real-world Evidence, capabilities of newer technologies for evidence generation within the industry. The event agenda will focus on key aspects such as Real-World Evidence Methodologies, FDA’ strategic framework, Applications of Artificial Intelligence…

Technologies Transforming Real-World Evidence (RWE) Evidence in the Pharmaceutical Industry

September 5, 2019September 5, 2019 MarketsandMarkets Conferences

As new drugs are emerging every day, it is very important to ensure that the patients get right and effective treatment. One such step can be taken from Real World Evidence (RWE). In simple words, Real World Evidence means data and information collected outside of a clinical trial. This data can be electronic medical records, medical charts or other medical claims to assess patient outcomes. It is made sure that the patient’s identity is removed from the previous data to maintain the patient’s privacy. However, today’s real-world evidence data is…

Speaker Interview With Stefan Glueck For 2ND Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

July 31, 2019 MarketsandMarkets Conferences

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. advances: more indication using ICI and combinations with chemo, and other IO. even brain metastases seem to respond to smart combinations. challenges: primary and secondary resistance and still less than 50% of patients even in…

Gene Therapy for Spinal Muscular Atrophy approved by FDA

July 26, 2019 MarketsandMarkets Conferences

A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Spinal Muscular Atrophy, a condition driven by defects in the SMN1 gene causing burdened babies lose muscle control, the medicine is designed to treat the disease. In the US each year about 400 babies is being affected by the illness and kills those with the most common type of the disease in a couple of years. The gene…

Speaker Interview with Silvia Cainarca for the 5th Annual Neuroscience R&D Technologies Conference

July 24, 2019July 24, 2019 MarketsandMarkets Conferences

London, UK July 24, 2019 – MarketsandMarkets recently interviewed Dr. Silvia Cainarca, Principal Investigator, iPSC Lab iTools & Solutions regarding the 5th Annual Neuroscience R&D Technologies Conference, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Q. What are the recent advances in Neuroscience R&D Technologies for Neurodegenerative disorders and current challenges that need immediate attention? A. Even if many powerful experimental animal models were set up in these years that can recapitulate the hallmark characteristics of different neuropathic diseases, one of the main challenges in their applicability…

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

July 15, 2019July 15, 2019 MarketsandMarkets Conferences

Washington D.C. [USA]: According to the Scientists, an autoimmune disease looks to be linked with testicular cancer that affects men. Known to us as ‘testicular cancer-associated paraneoplastic encephalitis’, it is the reason behind any serious neurological symptoms found in men. They lose control of the limbs, speech and eye movements progressively. The autoimmune disease starts with a testicular tumor, which seems to be the reason behind the immune system attacking the brain. Affected men find themselves undiagnosed or misdiagnosed often and relevant treatment is delayed. In a study that was published in…

Passage Bio on Producing Gene Therapies with Catalent’s Paragon

July 15, 2019 MarketsandMarkets Conferences

About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent’s paragon launched a unit that is devoted to manufacturing suite Paragon Harman’s, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it’s functional phase from mid-2020 and is support Passage Bio’s supply requirements from clinical through commercial phases. Stephen Squinto, P.hd, co-founder and Interim CEO at Passage Bio stated that “Passage will work contractually with Paragon to conduct GMP manufacturing…

Discussing effective, novel technology and recent discoveries of translational neuroscience in London

June 20, 2019June 20, 2019 MarketsandMarkets Conferences

London, UK, June 20th, 2019 – 5th Annual MarketsandMarkets Neuroscience R&D Technologies Conference will be discussing the latest technologies in the preclinical, translational neuroscience space. The conference will take place on 3rd and 4th October 2019 in London, UK also brings attention to new innovations of translational neuroscience imaging. This is a first ever conference focusing on applications of technology in developing neurological treatments where you will be able to meet global neuroscience heads from industry and academia. over the 2-days, 20+ industry leading speakers will be sharing their research &…